跳至主要内容
临床试验/ACTRN12620001263987
ACTRN12620001263987尚未招募未知

The effect of macrolide antibiotic de-escalation during the Australian summer season on exacerbations of obstructive airway diseases in adults: a double-blind placebo-controlled point-of-care randomised controlled trial

Hunter New England Local Health District0 个研究点目标入组 160 人开始时间: 2020年11月24日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • At least 18 years of age; currently receiving maintenance macrolide therapy (azithromycin, clarithromycin, roxithromycin or erythromycin) for the management of obstructive airway disease (asthma, COPD or bronchiectasis) for a period of at least 6 months; able to provide verbal informed consent; have access to a telephone; and willing to complete baseline and follow-up telephone interviews.

排除标准

  • Pregnant women (self-reported); patients with cystic fibrosis; the use of a macrolide for other conditions (e.g, mycobacterium avium complex infection, MAC) and unable to speak and understand English.

研究者

相似试验